Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in pediatric and young adult ALK-positive ALCL, IMT, and other solid tumors
NL-OMON50304Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigatinib in anaplastic large cell lymphoma (ALCL), inflammatory pseudotumor (IPT) and Nonhematologic neoplasms (3 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Dose-limiting toxicities, Pharmacokinetics and 3 more. Started Aug 2022; status: recruiting.
02
Drugs
brigatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON50304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50304.